Samsung Bioepis first acquires approval of Herceptin biosimilar in Europe
Samsung Bioepis(CEO/President Han-Seung Ko) has become the first to acquire sales approval of breast cancer biosimilar in Europe, away from other multinational pharmaceutical companies.
On the 20th(local time), Samsung Bioepis announced that the company acquired the final sales approval of ‘Ontr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
